Progesterone and pregnant mare serum gonadotropin improve the reproductive capacity of long-term non-oestrus replacement gilts

2019 ◽  
Vol 59 (12) ◽  
pp. 2184 ◽  
Author(s):  
Peng Zheng ◽  
Fushuo Huang ◽  
Mingjun Ma ◽  
Yaguang Tian ◽  
He Huang
Keyword(s):  
Reproductive Potential ◽  
Gonadotropin Releasing Hormone ◽  
Reproductive Capacity ◽  
Control Group ◽  
Releasing Hormone ◽  
Pregnant Mare Serum Gonadotropin ◽  
Group A ◽  
Serum Gonadotropin ◽  
Group B

Context It is a common problem that replacement gilts exhibit delayed oestrus and non-oestrus in pig production. Aims This study explored the use of progesterone and pregnant mare serum gonadotropin (PMSG) to promote oestrus and to restore the reproductive capacity of sows. Methods A total of 90 long-term non-oestrus replacement gilts were randomly divided into three groups. Group A consisted of 30 sows that were normally fed for 20 days, followed by injections of 1000 IU of PMSG on the morning of the 21st day and 100 μg of gonadotropin-releasing hormone on the 24th day. Group B consisted of 30 sows that were continuously fed with altrenogest (20 mg/head.day) for 18 days, followed by injections of 1000 IU of PMSG on the morning of the 21st day and 100 μg of gonadotropin-releasing hormone on the 24th day. Group C (control group) consisted of 30 sows that were normally fed for 20 days, followed by injections of 3 mL of physiological saline on the morning of the 21st day and 3 mL of saline on the 24th day. Oestrus identification was performed in all three groups, and sows underwent artificial insemination after the injection of gonadotropin-releasing hormone or saline. Key results We found that the follicles of long-term non-oestrus replacement gilts were not developed, and follicle diameters were <4 mm. The oestrus rate and pregnancy rate of the sows in Group B were significantly lower than those in Group A (30% vs 66.7% and 66.7% vs 90%) respectively. There was no difference in the litter size between Group A and Group B (11.2 vs 11.5). The sows in Group C exhibited no oestrus and no pregnancy. After treatment with progesterone and PMSG, the follicle diameters of sows in oestrus were significantly greater than those of sows in non-oestrus, and the levels of oestradiol, luteinising hormone and follicle-stimulating hormone were significantly higher than those of sows in non-oestrus. Conclusions This study showed that progesterone and PMSG treatment can alter the reproductive hormone levels and follicle diameters in long-term non-oestrus replacement gilts, promote oestrus and restore reproductive capacity in sows. Implications This study provides a method for the use of hormone-treated gilts to maximise the reproductive potential of gilts.

Developmental changes in the gonadotropin releasing hormone neuron of the female rabbit: effects of tamoxifen citrate and pregnant mare serum gonadotropin

1993 ◽  
Vol 71 (10-11) ◽  
pp. 761-767 ◽  
Author(s):  
Warren G. Foster ◽  
John F. Jarrell ◽  
Edward V. YoungLai
Keyword(s):  
Gonadotropin Releasing Hormone ◽  
Developmental Changes ◽  
Tamoxifen Treatment ◽  
Control Group ◽  
Releasing Hormone ◽  
Pregnant Mare Serum Gonadotropin ◽  
Age Related ◽  
Developmental Shift ◽  
Tamoxifen Citrate ◽  
Serum Gonadotropin

Developmental changes in immunostained gonadotropin releasing hormone neurons were demonstrated in female rabbits assigned to the following treatment groups: (i) tamoxifen citrate, 10 mg∙kg−1∙day−1, in sesame seed oil (vehicle) (n = 24) or (ii) vehicle alone (control, n = 24) for 108 days; and (iii) 50 IU of pregnant mare serum gonadotropin on postnatal days 22 and 25 (n = 24) or vehicle on nontreatment days. Treatments had no effect on the total number of immunostained cells, but there was a significant (p = 0.0160) developmental shift from cells with smooth processes to rough. Group comparisons revealed that there was a significant (p < 0.001) age-related increase in the number of rough cells in pregnant mare serum treated rabbits between days 25 and 75, indicating an advancement in the shift from smooth to rough cells. Plasma gonadotropin levels, ovarian follicular development, and the developmental shift from smooth to rough cells were markedly suppressed by tamoxifen treatment compared with rabbits of the control group, while no difference in estradiol levels were found. Our results suggest that a developmental shift in gonadotropin releasing hormone cell morphology from smooth to rough precedes sexual maturity in the female rabbit.Key words: development, sexual maturation, gonadotropin releasing hormone, puberty, immunohistochemistry.

scholarly journals A Prospective Randomized Trial to Assess the Antireflux Effect of Antireflux Mucosectomy in the Porcine Model

2019 ◽  
Vol 2019 ◽  
pp. 1-6
Author(s):  
Xuan Li ◽  
Weifeng Zhang ◽  
Meihong Chen ◽  
Shuchun Wei ◽  
Xiangyang Zhao ◽  
...  
Keyword(s):  
Gastroesophageal Reflux Disease ◽  
Proton Pump Inhibitor ◽  
Porcine Model ◽  
Gastroesophageal Junction ◽  
Control Group ◽  
Potential Efficacy ◽  
Significant Difference ◽  
Group A ◽  
Group B

Background. Both long-term proton pump inhibitor use and surgical fundoplication have potential drawbacks as treatments for chronic gastroesophageal reflux disease (GERD). Our aim was to investigate the potential efficacy of antireflux mucosectomy (ARMS) in porcine and determine the optimal circumference of resection in relation to gastroesophageal junction (GEJ). Methods. Nine pigs were allocated into the following 3 groups by computerized randomization: group A: control, group B: 1/3 circumference of the esophagus, and group C: 2/3 circumference of the esophagus. We performed mucosectomy with a crescentic mucosal resection at 3 cm above the GEJ and 1 cm below the GEJ. The animals were kept on a liquid diet for 24 h prior to endoscopy. At 6 weeks, animals underwent esophagoscopy, barium radiography, gastric yield pressure (GYP), and gastric yield volume (GYV) determination. Results. The weight of swines has no significant difference, and all pigs had maintained their weight after the procedure. We both found scar formation at the GEJ in group B and C. Compared with group A and B, group C produced significantly higher GYP (24.23±3.42 mmHg, p=0.004) and significantly smaller GYV (2200.0±238.96 mL, p=0.028) after 6 weeks. Barium radiography showed that the width of the cardia was narrower (13.73±1.19 mm, p=0.032) in group C after 6-week postprocedure. Conclusion. Our study demonstrated the potential antireflux effect of ARMS. We also recommend the 2/3 circumference resection of mucosa at 3 cm distance from the GEJ.

scholarly journals Abiraterone versus bicalutamide in combination with gonadotropin releasing hormone antagonist therapy for high risk metastatic hormone sensitive prostate cancer.

2021 ◽  
Author(s):  
Takashi Ueda ◽  
Takumi Shiraishi ◽  
Saya Ueda ◽  
Motoharu Ohashi ◽  
Toru Matsugasumi ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Progression Free Survival ◽  
Gonadotropin Releasing Hormone ◽  
Free Survival ◽  
Releasing Hormone ◽  
Group A ◽  
Psa Progression ◽  
Hormone Sensitive ◽  
Group B

Abstract ObjectivesTo compare the efficacy of abiraterone with that of bicalutamide in combination with gonadotropin-releasing hormone antagonist treatment for high risk metastatic hormone-sensitive prostate cancer patients.MethodsOne hundred and forty-nine patients with high risk metastatic hormone-sensitive prostate cancer at our hospital and affiliated hospitals between December 2013 and July 2020 were retrospectively identified. Fifty patients were administered abiraterone (1000mg/day) plus prednisolone (5mg/day) with gonadotropin-releasing hormone antagonist (degarelix) (group A) and 99 patients were administered bicalutamide (80mg/day) with gonadotropin-releasing hormone antagonist (group B). ResultsPSA- progression-free survival of group A was significantly longer than that of group B. Abiraterone therapy and Gleason score were significant independent factors for PSA-progression-free survival. By propensity score matching, total 56 matched patients were obtained. PSA-PFS (p<0.001) and OS (p=0.0071) of high risk mHNPC patients were significantly longer in abiraterone group of matched patients. Abiraterone therapy and Gleason score were still shown to be significant independent factors for PSA-PFS in matched patients.ConclusionsPSA-progression-free survival and overall survival in patients who were treated with abiraterone in combination with gonadotropin releasing hormone antagonist were significantly better than those of bicalutamide.

408 HOLSTEIN DONORS RESPONSE USING OR NOT USING ESTRADIOL 17-β IN THE SUPEROVULATORY TREATMENT

2010 ◽  
Vol 22 (1) ◽  
pp. 361
Author(s):  
S. Fuentes ◽  
D. Ruiz ◽  
P. Vera ◽  
A. Castro ◽  
I. Moreno ◽  
...  
Keyword(s):  
Treatment Protocol ◽  
Gonadotropin Releasing Hormone ◽  
Holstein Cows ◽  
The European Union ◽  
Treatment Protocols ◽  
Releasing Hormone ◽  
Lactating Cows ◽  
Group A ◽  
Group B ◽  
Rectal Palpation

Because of new regulations banning the use of estradiol in the European Union and other countries, the present study was designed to determine the efficacy of an alternative to the use of estradiol 17-β in superovulation of Holstein cows and heifers. A total of 61 lactating cows and 49 heifers (15-18 months old) were divided into 2 groups: Group A (32 cows and 22 heifers) and Group B (29 cows and 27 heifers). Animals in Group A received a CIDR device (Pfizer, Madrid, Spain) for 13 days. At the same time of CIDR insertion and 5 days later, all animals received 2 mL (0.15 mg) of d-cloprostenol (PGF; Veteglan®, Calier, Spain). Gonadotropin-releasing hormone (0.5 mg of gonadorelin; Fertagyl®, Schering-Plough, Carbajosa de la Sagrada, Spain) was administered twice, 36 h after the second PGF and 24 h after CIDR removal. Superovulation treatments were initiated 36 h after the first GnRH, with a total dose of 15 mL (750 IU) of FSH (Pluset®, Calier, Spain) for cows and 11.5 mL (575 IU) for heifers, given in 10 twice-daily injections that decreased in dose. Luteolysis was induced with 0.15 mg of PGF given twice, 12 h before and also at the time of CIDR removal. Animals in Group B received a CIDR device for 7 days. Twenty-four hours after CIDR insertion, all animals received 100 mg of progesterone (Smithkline, Tres Cantos, Spain) and 5 mg of estradiol 17-β (Sigma, St. Louis, MO, USA). Beginning on Day 5, animals were superovulated with similar doses of FSH to those used in Group A. Luteolysis was induced with 0.15 mg of PGF given twice, 12 h before CIDR removal and also at the time of removal. Gonadotropin-releasing hormone (0.5 mg) was administered at the time of AI. Animals from both groups were inseminated with frozen-thawed semen at 12 and 24 h after the onset of standing estrus. Embryos were recovered nonsurgically 7 days later. A total of 299 frozen-thawed embryos (Freeze Control® CL5500, Bioniche, Belleville, Ontario, Canada) from both groups were transferred in synchronized Holstein heifers. Pregnancy was confirmed by rectal palpation on Day 40 to 45 of gestation. Data were analyzed by two-way ANOVA and results are shown in the table. No significant differences were found between cows and heifers, nor was there a difference between groups. These results showed that the previous superovulatory treatment using progesterone and estradiol can be successfully replaced with the treatment protocol described herein. Table 1.Mean number of recovered ova/embryos, transferable embryos, and pregnancy rates after embryo transfer (ET) in Holstein cows and heifers superovulated with 2 treatment protocols

scholarly journals Do Mechanical and Physicochemical Properties of Orthodontic NiTi Wires Remain Stable In Vivo?

2016 ◽  
Vol 2016 ◽  
pp. 1-5 ◽  
Author(s):  
Michał Sarul ◽  
Małgorzata Rutkowska-Gorczyca ◽  
Jerzy Detyna ◽  
Anna Zięty ◽  
Maciej Kawala ◽  
...  
Keyword(s):  
Negative Influence ◽  
Nanoindentation Test ◽  
Control Group ◽  
Physiochemical Properties ◽  
Microscopic Evaluation ◽  
Group A ◽  
Group B ◽  
Niti Wires

Introduction and Aim.Exceptional properties of the NiTi archwires may be jeopardized by the oral cavity; thus its long-term effect on the mechanical and physiochemical properties of NiTi archwires was the aim of work.Material and Methods. Study group comprised sixty 0.016×0.022 NiTi archwires from the same manufacturer evaluated (group A) after the first 12 weeks of orthodontic treatment. 30 mm long pieces cut off from each wire prior to insertion formed the control group B. Obeying the strict rules of randomization, all samples were subjected to microscopic evaluation and nanoindentation test.Results.Both groups displayed substantial presence of nonmetallic inclusions. Heterogeneity of the structure and its alteration after usage were found in groups B and A, respectively.Conclusions.Long-term, reliable prediction of biomechanics of NiTi wires in vivo is impossible, especially new archwires from the same vendor display different physiochemical properties. Moreover, manufacturers have to decrease contamination in the production process in order to minimize risk of mutual negative influence of nickel-titanium archwires and oral environment.

scholarly journals The Effect of Apigenin on Pharmacokinetics of Imatinib and Its Metabolite N-Desmethyl Imatinib in Rats

2013 ◽  
Vol 2013 ◽  
pp. 1-6 ◽  
Author(s):  
Xian-yun Liu ◽  
Tao Xu ◽  
Wan-shu Li ◽  
Jun Luo ◽  
Pei-wu Geng ◽  
...  
Keyword(s):  
Single Dose ◽  
Pharmacokinetic Parameters ◽  
Control Group ◽  
Term Study ◽  
Long Term Study ◽  
Short Term Study ◽  
Term Administration ◽  
Group A ◽  
Group B

The purpose of this study was to determine the effect of apigenin on the pharmacokinetics of imatinib and N-desmethyl imatinib in rats. Healthy male SD rats were randomly divided into four groups: A group (the control group), B group (the long-term administration of 165 mg/kg apigenin for 15 days), C group (a single dose of 165 mg/kg apigenin), and D group (a single dose of 252 mg/kg apigenin). The serum concentrations of imatinib and N-desmethyl imatinib were measured by HPLC, and pharmacokinetic parameters were calculated using DAS 3.0 software. The parameters ofAUC(0-t),AUC(0−∞),Tmax,Vz/F, andCLz/Ffor imatinib in group B were different from those in group A (P<0.05). Besides,MRT(0−t)andMRT(0−∞)in groups C and D differed distinctly from those in group A as well. The parameters ofAUC(0-t)andCmaxfor N-desmethyl imatinib in group C were significantly lower than those in group A (P<0.05); however, compared with groups B and D, the magnitude of effect was modest. Those results indicated that apigenin in the short-term study inhibited the metabolism of imatinib and its metabolite N-desmethyl imatinib, while in the long-term study the metabolism could be accelerated.

No Evidence for the Benefit of Gonadotropin-Releasing Hormone Agonist in Preserving Ovarian Function and Fertility in Lymphoma Survivors Treated With Chemotherapy: Final Long-Term Report of a Prospective Randomized Trial

2016 ◽  
Vol 34 (22) ◽  
pp. 2568-2574 ◽  
Author(s):  
Isabelle Demeestere ◽  
Pauline Brice ◽  
Fedro A. Peccatori ◽  
Alain Kentos ◽  
Jehan Dupuis ◽  
...  
Keyword(s):  
Ovarian Reserve ◽  
Ovarian Function ◽  
Follicle Stimulating Hormone ◽  
Gonadotropin Releasing Hormone ◽  
Control Group ◽  
Releasing Hormone ◽  
Gonadotropin Releasing Hormone Agonist ◽  
Stimulating Hormone

Purpose We have reported previously that after 1-year follow up, gonadotropin-releasing hormone agonist (GnRHa) did not prevent chemotherapy-induced premature ovarian failure (POF) in patients with lymphoma, but may provide protection of the ovarian reserve. Here, we report the final analysis of the cohort after 5 years of follow up. Patients and Methods A total of 129 patients with lymphoma were randomly assigned to receive either triptorelin plus norethisterone (GnRHa group) or norethisterone alone (control group) during chemotherapy. Ovarian function and fertility were reported after 2, 3, 4, and 5 to 7 years of follow up. The primary end point was POF, defined as at least one follicle-stimulating hormone value of > 40 IU/L after 2 years of follow up. Results Sixty-seven patients 26.21 ± 0.64 years of age had available data after a median follow-up time of 5.33 years in the GnRHa group and 5.58 years in the control group (P = .452). Multivariate logistic regression analysis showed a significantly increased risk of POF in patients according to age (P = .047), the conditioning regimen for hematopoietic stem cell transplant (P = .002), and the cumulative dose of cyclophosphamide > 5 g/m2 (P = .019), but not to the coadministration of GnRHa during chemotherapy (odds ratio, 0.702; P = .651). The ovarian reserve, evaluated using anti-Müllerian hormone and follicle-stimulating hormone levels, was similar in both groups. Fifty-three percent and 43% achieved pregnancy in the GnRHa and control groups, respectively (P = .467). Conclusion To the best of our knowledge, this is the first long-term analysis confirming that GnRHa is not efficient in preventing chemotherapy-induced POF in young patients with lymphoma and did not influence future pregnancy rate. These results reopen the debate about the drug’s benefit in that it should not be recommended as standard for fertility preservation in patients with lymphoma.

scholarly journals A retrospective, observational, single center study of gonadotropin-releasing hormone agonist protocols at the Reproductive Center of Farah Hospital in Jordan

2019 ◽  
Vol 7 (8) ◽  
pp. 3103
Author(s):  
Zaid Kilani ◽  
Mohammad Shaban
Keyword(s):  
Term Treatment ◽  
Gonadotropin Releasing Hormone ◽  
Clinical Pregnancy ◽  
Short Term ◽  
Short Term Treatment ◽  
Releasing Hormone ◽  
Long Term Treatment ◽  
Group A

Background: Data on infertility and in vitro fertilization (IVF) are incomplete and uncertain in Jordan and worldwide because of difficulties in evaluating infertility in the general population. This study aimed at comparing the effectiveness of the gonadotropin-releasing hormone agonists (GnRH-a) long and short protocols as part of IVF or intracytoplasmic sperm injection.Methods: This observational, retrospective, comparative, longitudinal study was conducted in a reproductive center in Jordan. It reviewed data charts from women who took GnRH-a for IVF, from 2010 to 2013. These were categorized in Group A (long-term GnRH-a: single 3.75 mg-monthly injection) or Group B (short-term GnRH-a: multiple daily 0.1 mg injections). The primary endpoint was the rate of ongoing clinical pregnancy (number of pregnancies/number of women) and live birth rate in fresh cycle/protocols.Results: Out of 1,946 eligible women, 471 underwent the long-term treatment of GnRH-a administration and 1,523 the short-term treatment. The women’s mean age was 29.61±3.80 years old. Out of the 471 women in Group A, 216 (45.9%) women had ongoing clinical pregnancy, of whom 69 (31.9%) had live births. In the short-protocol group, 485 (31.8%) women had ongoing clinical pregnancy, of whom 133 (27.4%) had live births.Conclusions: GnRH-a long protocol is more effective than the short protocol regardless of the agonist formulation used in subfertile women/men who underwent IVF/ intracytoplasmic sperm injection.

Sign in / Sign up

Export Citation Format

Share Document